4 terminated. 4 Phase 3, 1 Phase 2.
By phase and status
Follow Eylea: new trials by email Literature Review of Eylea trials Research Report on Eylea
Trials (filtered) newest first · largest first
All 4 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)
KSI-301, Aflibercept, Sham Procedure - Diabetic Macular Edema | Phase 3 | Terminated | 459 | 2020-09-30 | 2024-08-22 |
A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)
KSI-301, Aflibercept, Sham Procedure - Diabetic Macular Edema | Phase 3 | Terminated | 460 | 2020-09-30 | 2024-08-22 |
A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration.
KSI-301, Aflibercept, Sham Procedure - Wet Macular Degeneration | Phase 2 / Phase 3 | Terminated | 559 | 2019-10-08 | 2024-07-18 |
Study of Safety and Efficacy of Brolucizumab 6 mg Dosed Every 4 Weeks Compared to Aflibercept 2 mg Dosed Every 4 Weeks in Patients With Retinal Fluid Despite Frequent Anti-VEGF Injections
Brolucizumab, Aflibercept - Age-Related Macular Degeneration | Phase 3 | Terminated | 535 | 2018-10-30 | 2023-01-30 |
Conditions studied
Eye Diseases (3) · Retinal Degeneration (3) · Retinal Diseases (3) · Vision Disorders (3) · Vision, Low (3) · Diabetes Mellitus (2) · Diabetic Retinopathy (2) · Macular Degeneration (2) · Macular Edema (2) · Neurofibromatosis 2 (1) · Wet Macular Degeneration (1)
Sponsors
Kodiak Sciences Inc (3) · Novartis Pharmaceuticals (1)
Countries
United States (4) · Puerto Rico (3) · Czechia (2) · Germany (2) · Hungary (2) · Italy (2) · Latvia (2) · Poland (2) · Slovakia (2) · Spain (2) · France (1) · Israel (1)
Top investigators
Pablo Velazquez-Martin, MD (3)